Vaginal Panel Testing Market Trends, and Forecast, 2021-2031

Home Testing Paves Way for eCommerce Expansion Post Coronavirus Outbreak

The coronavirus outbreak has subsided significantly, as the end of 2021 is nearing. This outbreak led to several developments in the healthcare industry, especially in the vaginal panel testing market in EMEA. The trend of home testing has benefitted healthcare companies within the market landscape. This is why manufacturers are tapping revenue opportunities through eCommerce to expand their revenue streams.

Since manufacturers witnessed supply shortage for laboratory items during the peak pandemic period, companies in the vaginal panel testing market in EMEA are increasing efforts to maintain optimum inventory levels. Surge in spending capacity of individuals and relaxation of COVID-19 restrictions across countries is contributing toward the increase in overall revenue flow in the market.

Read Report Overview@ https://www.transparencymarketresearch.com/europe-middle-east-africa-vaginal-panel-testing-market.html

Next-gen Assays Help Fewer Recurrent Doctor Office Visits

Companies are increasing the production of molecular nucleic acid amplification tests (NAAT) to support the detection of vaginitis and vaginosis. The high prevalence of candida vaginitis, trichomoniasis, and bacterial vaginosis (BV) among women has led to innovations in assays. Manufacturers are increasing the availability of vaginitis panels that aid in the detection of yeast infections and trichomoniasis.

The vaginal panel testing market in EMEA is projected to cross US$ 175 Mn by 2031. Companies are increasing R&D in assays that enable better guided drug treatment, reduced suffering in affected women, and fewer recurrent doctor's office visits. Such assays are helping healthcare companies to advance in molecular testing.

Innovations in Panels Help in Detection of Sexual and Vaginal Disease States

The vaginal panel testing market in EMEA is slated to clock a CAGR of 3.9% during the forecast period. Nevertheless, intensified competition in the market is challenging companies to develop an assay portfolio that caters to both sexual and vaginal health, which includes vaginitis testing alongside comprehensive sexually transmitted infections (STIs) and viral load testing.

Get Sample Copy of the Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84178

There is a growing demand for vaginal panels that provide the flexibility to detect several infections and disease states with only one vaginal swab, which includes gonorrhea and candida species. Since the CDC (Centers for Disease Control and Prevention) is recommending the testing of trichomonas vaginalis (TV) in all women seeking treatment for vaginal discharge, such findings are leading to product sales.

At-home Vaginal Panel Testing Products Provide Privacy and Convenience to Women

Privacy and convenience are becoming important factors in the vaginal panel testing market in EMEA. This has led to innovations in affordable at-home testing products. Manufacturers in the vaginal panel testing market in EMEA are boosting the production of lab certified vaginal panels that help to generate results in less than five days. Since many women are concerned for unusual changes in the color, odor, and texture of vaginal discharge, at-home vaginal panel testing products are providing them several advantages.

At-home vaginal panel testing products eliminate the need of awkward conversations with peers and physicians, and help to screen common causes of abnormal vaginal discharge at comfort of the home.

Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=84178

FDA-authorized Products Enable Companies to Gain Competitive Edge

Molecular testing using a DNA probe for the detection of candida species and gardnerella vaginalis is growing prominent in the vaginal panel testing market in EMEA. Companies are increasing research in this space, since vaginitis accounts for several doctor office visits each year. Since the complications of BV can be significant in pregnant women, manufacturers are boosting output capacities in vaginal panel testing products.

In order to boost credibility, companies in the vaginal panel testing market in EMEA are increasing the availability of FDA-authorized products. These include polymerase chain reaction (PCR) assay and microbiome-based vaginal panel tests. Companies are innovating in assays that support antimicrobial resistance initiatives in women by detecting the presence of Candida krusei and C. glabrata.

Europe and Middle East & Africa Vaginal Panel Testing Market: Overview

Vaginal panel testing is an automated qualitative in vitro diagnostic test for the direct detection of DNA targets from bacteria associated with bacterial vaginosis, candida species associated with vulvovaginal candidiasis, and trichomonas vaginalis
The test utilizes real-time polymerase chain reaction (PCR) for the amplification of specific DNA targets and utilizes fluorogenic target-specific hybridization probes to detect and differentiate DNA from
Vaginal panel assists in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis

Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=84178

 Europe and Middle East & Africa Vaginal Panel Testing Market: Key Drivers

Accurate screening & detection of bacterial, yeast, fungi, and viral samples in clinical pathology using vaginal testing panels has allowed less turnaround time due to lower chances of producing false positive results because of their broad coverage of microbes of different classes, sensitivity, and effectiveness for the production of the results. This will help in more women undergoing diagnostic tests for vaginal testing, which, in turn, is likely to increase the number of diagnostic vaginal testing procedures.

Moreover, incidence of vaginal disorders is common among young women, and around 32% of the female population struggles with different kinds of vaginal complications. Most vaginal infections are asymptomatic and hence, it is difficult to predict the initial onset. Therefore, more women are likely to undergo molecular diagnostic tests for vaginal infections, which is projected drive the global vaginal testing panels market.

Market Segmentation: Europe and Middle East & Africa Vaginal Panel Testing Market

In terms of type, the vaginal panel testing market in EMEA has been bifurcated into direct molecular DNA probe and molecular nucleic acid amplification test (NAAT)

Based on application, the vaginal panel testing market in EMEA has been classified into bacterial vaginosis, vulvovaginal candidiasis, chlamydia, gonorrhoea, trichomoniasis, and others
In terms of end-user, the vaginal panel testing market in EMEA has been divided into hospitals, diagnostic laboratories, and others
Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The vaginal panel testing market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=84178

Regional Overview: Europe and Middle East & Africa Vaginal Panel Testing Market

Europe dominated the vaginal panel testing market in EMEA in 2020, accounting for 87.9% share. Increase in health awareness, rise in expenditure on healthcare infrastructure, and surge in demand for better healthcare facilities fuel the growth of the vaginal testing panels market in Europe.
Germany is projected to be an attractive market from 2021 to 2031. The country is anticipated to account for significant share of the market in Europe during the forecast period. Growth of the market in the country can be attributed to increase in research activities, rise in government funding for research & development, and surge in the number of biotechnology companies.

Major Players

The vaginal panel testing market report concludes with the company profiles section, which includes key information about major players in the vaginal panel testing market in EMEA
Leading players analyzed in the report include
Abbott Laboratories
Atrida
Becton
Dickenson and Company
Cepheid (Danaher Corporation)
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Laboratory Corporation of America Holdings
Mologic Ltd.
QIAGEN
Quest Diagnostics Incorporated
Quidel Corporation

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: 1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.